Van Eck Associates Corp Compugen LTD Transaction History

Van Eck Associates Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$1.57 - $3.33 $33,638 - $71,348	-21,426 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$2.76 - $4.64 $331 - $556	120 Added 0.56%	21,426 $69,000
Q4 2021 Jan 26, 2022	SELL	$4.09 - $7.16 $3,533 - $6,186	-864 Reduced 3.9%	21,306 $92,000
Q3 2021 Nov 03, 2021	SELL	$5.8 - $8.02 $10,335 - $14,291	-1,782 Reduced 7.44%	22,170 $132,000
Q2 2021 Aug 10, 2021	BUY	$6.87 - $9.16 $14,935 - $19,913	2,174 Added 9.98%	23,952 $198,000
Q1 2021 May 13, 2021	BUY	$7.67 - $13.77 $167,037 - $299,883	21,778 New	21,778 $187,000

13.1M

79.2K

12.7K

Ticker CGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,600
Market Cap $130M
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tu...

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

Stay updated on Van Eck Associates Corp with notifications on news.